Wiskott-Aldrich Syndrome [clinicaltrials_resource:307e919a6cf9fde751c0024174a95d9b]
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders [clinicaltrials:NCT00004341]Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies [clinicaltrials:NCT00006054]Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome [clinicaltrials:NCT00160355]Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients [clinicaltrials:NCT00220766]clinicaltrials:NCT00278954Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells [clinicaltrials:NCT00730314]Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) [clinicaltrials:NCT00885833]Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients [clinicaltrials:NCT00909363]clinicaltrials:NCT01289847clinicaltrials:NCT01319851Gene Therapy for Wiskott-Aldrich Syndrome (WAS) [clinicaltrials:NCT01347242]Gene Therapy for WAS [clinicaltrials:NCT01347346]Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome [clinicaltrials:NCT01410825]Gene Therapy for Wiskott-Aldrich Syndrome [clinicaltrials:NCT01515462]Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT01529827]Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies [clinicaltrials:NCT01652092]Immune Disorder HSCT Protocol [clinicaltrials:NCT01821781]clinicaltrials:NCT01852370clinicaltrials:NCT01917708Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 [clinicaltrials:NCT02064933]Gene Therapy for WAS Follow-up [clinicaltrials:NCT02333760]Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells [clinicaltrials:NCT02512679]
condition [clinicaltrials_vocabulary:condition]
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders [clinicaltrials:NCT00004341]Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies [clinicaltrials:NCT00006054]Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome [clinicaltrials:NCT00160355]Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients [clinicaltrials:NCT00220766]clinicaltrials:NCT00278954Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells [clinicaltrials:NCT00730314]clinicaltrials:NCT00774358Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) [clinicaltrials:NCT00885833]Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients [clinicaltrials:NCT00909363]clinicaltrials:NCT01289847clinicaltrials:NCT01319851Gene Therapy for Wiskott-Aldrich Syndrome (WAS) [clinicaltrials:NCT01347242]Gene Therapy for WAS [clinicaltrials:NCT01347346]Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome [clinicaltrials:NCT01410825]Gene Therapy for Wiskott-Aldrich Syndrome [clinicaltrials:NCT01515462]Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT01529827]Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies [clinicaltrials:NCT01652092]Immune Disorder HSCT Protocol [clinicaltrials:NCT01821781]clinicaltrials:NCT01852370clinicaltrials:NCT01917708Participation in a Research Registry for Immune Disorders [clinicaltrials:NCT01953016]Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 [clinicaltrials:NCT02064933]Gene Therapy for WAS Follow-up [clinicaltrials:NCT02333760]Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells [clinicaltrials:NCT02512679]
condition browse [clinicaltrials_vocabulary:condition-browse]
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders [clinicaltrials:NCT00004341]Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies [clinicaltrials:NCT00006054]Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome [clinicaltrials:NCT00160355]Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients [clinicaltrials:NCT00220766]clinicaltrials:NCT00278954Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells [clinicaltrials:NCT00730314]clinicaltrials:NCT00774358Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) [clinicaltrials:NCT00885833]Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients [clinicaltrials:NCT00909363]clinicaltrials:NCT01289847clinicaltrials:NCT01319851Gene Therapy for Wiskott-Aldrich Syndrome (WAS) [clinicaltrials:NCT01347242]Gene Therapy for WAS [clinicaltrials:NCT01347346]Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome [clinicaltrials:NCT01410825]Gene Therapy for Wiskott-Aldrich Syndrome [clinicaltrials:NCT01515462]Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT01529827]Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies [clinicaltrials:NCT01652092]Immune Disorder HSCT Protocol [clinicaltrials:NCT01821781]clinicaltrials:NCT01852370clinicaltrials:NCT01917708Participation in a Research Registry for Immune Disorders [clinicaltrials:NCT01953016]Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 [clinicaltrials:NCT02064933]Gene Therapy for WAS Follow-up [clinicaltrials:NCT02333760]Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells [clinicaltrials:NCT02512679]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
eligibility for clinicaltrials:NCT00613561 [clinicaltrials_resource:6ced5959ba1956bb732498eea3f9340f]eligibility for clinicaltrials:NCT01852370 [clinicaltrials_resource:bfa708147930b2d70394ab76f9046a70]eligibility for clinicaltrials:NCT01962415 [clinicaltrials_resource:f9a1a94029c8e9dfe6a296d3517699a8]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00613561 [clinicaltrials_resource:6ced5959ba1956bb732498eea3f9340f]eligibility for clinicaltrials:NCT01852370 [clinicaltrials_resource:bfa708147930b2d70394ab76f9046a70]eligibility for clinicaltrials:NCT01962415 [clinicaltrials_resource:f9a1a94029c8e9dfe6a296d3517699a8]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Wiskott-Aldrich Syndrome [clinicaltrials_resource:307e919a6cf9fde751c0024174a95d9b]
Bio2RDF identifier
307e919a6cf9fde751c0024174a95d9b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:307e919a6cf9fde751c0024174a95d9b
identifier
clinicaltrials_resource:307e919a6cf9fde751c0024174a95d9b
title
Wiskott-Aldrich Syndrome
@en
type
label
Wiskott-Aldrich Syndrome [clinicaltrials_resource:307e919a6cf9fde751c0024174a95d9b]
@en
Wiskott-Aldrich Syndrome